NanoOncology
Biotechnology - Madison, Wisconsin, United States
NanoOncology Employees
NanoOncology Details
MissionWe at NANO are committed to altering the treatment paradigms of cancer. We believe that permanent remission of cancer and disease-free survival can be achieved through molecular therapies that are specific for each individual. It is our mission to indentify specific tumor-causing genetic targets and designing small interfering RNA (siRNA)-based drugs and small molecule drugs that inhibit the tumor promoting function of gene products for each patient on an individual basis. OverviewNANO is a seed-stage biopharmaceutical company that was founded in 2010. The company has laboratory and office space at the Fitchburg Technology Campus, 5520 Nobel Drive, Suite 160, Madison, Wisconsin. NANO invented and submitted provisional patent applications for an siRNA therapeutic drug that targets the EVI1 gene, called EVIRNA, for treatment of advanced breast, prostate, lung, colon, ovarian, and skin cancer and may be used initially as a second-line therapy, and advanced to first-line therapy once proven effective as a stand-alone treatment.NANO was acquired by PeptiMed in 2011.
NanoOncology Technologies
Load Balancers
Nginx
Advertising Networks
Baidu Ads
Other
Mobile Friendly